Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 7
Submit an article Journal homepage
139
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)

Ali G. TurhanINSERM UMR-S935, Campus CNRS, Villejuif, France; ;Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France; ;INGESTEM-ESTeam Paris Sud, Villejuif, France; ;Service d’Onco-Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Paul Brousse, Villejuif, France; ;Service d’Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Correspondence[email protected]
,
Patricia HuguesINSERM UMR-S935, Campus CNRS, Villejuif, France;
,
Nathalie SorelCHU de Poitiers, Service de Cancérologie Biologique, Poitiers, France;
,
Christophe DesterkeINSERM UMR-S935, Campus CNRS, Villejuif, France; ;Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France;
,
Jean-Henri BourhisDépartement d’Hématologie, Institut Gustave Roussy, Villejuif, France
,
Annelise Bennaceur-GriscelliINSERM UMR-S935, Campus CNRS, Villejuif, France; ;Paris Saclay, Faculté de Médecine, Université Paris Sud, Le Kremlin-Bicêtre, France; ;INGESTEM-ESTeam Paris Sud, Villejuif, France; ;Service d’Onco-Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Paul Brousse, Villejuif, France; ;Service d’Hématologie, AP-HP Hôpitaux Universitaires Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France;
&
Jean-Claude ChomelINSERM UMR-S935, Campus CNRS, Villejuif, France; ;CHU de Poitiers, Service de Cancérologie Biologique, Poitiers, France;
show all
Pages 1719-1723 | Received 06 Dec 2019, Accepted 16 Feb 2020, Published online: 03 Mar 2020

References

  • Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346–357.
  • Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (stim1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298–305.
  • Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757.
  • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–430.
  • Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657–3660.
  • Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565–5572.
  • Bocchia M, Sicuranza A, Abruzzese E, et al. Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. Front Oncol. 2018;8:194.
  • Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget. 2016;7(23):35293–35301.
  • Kumari A, Brendel C, Hochhaus A, et al. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119(2):530–539.
  • Chomel JC, Sorel N, Guilhot J, et al. BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. Blood. 2012;119(12):2964–2965.
  • Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7(1):48–58.
  • Krämer A, Löffler H, Bergmann J, et al. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia. Leukemia. 2001;15(1):62–68.
  • Bruns I, Czibere A, Fischer JC, et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia. 2009;23(5):892–899.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.